Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine

Meningococcal disease is a major cause of morbidity and mortality worldwide. Its epidemiology is currently dominated by five capsular serogroups (A, B, C, W, and Y). While effective vaccines already exist for serogroups A, C, W and Y, except for under clonal outbreaks, no vaccine was available again...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2014-03, Vol.32 (11), p.1273-1279
Hauptverfasser: Tani, Chiara, Stella, Maria, Donnarumma, Danilo, Biagini, Massimiliano, Parente, Pierino, Vadi, Alessandro, Magagnoli, Claudia, Costantino, Paolo, Rigat, Fabio, Norais, Nathalie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1279
container_issue 11
container_start_page 1273
container_title Vaccine
container_volume 32
creator Tani, Chiara
Stella, Maria
Donnarumma, Danilo
Biagini, Massimiliano
Parente, Pierino
Vadi, Alessandro
Magagnoli, Claudia
Costantino, Paolo
Rigat, Fabio
Norais, Nathalie
description Meningococcal disease is a major cause of morbidity and mortality worldwide. Its epidemiology is currently dominated by five capsular serogroups (A, B, C, W, and Y). While effective vaccines already exist for serogroups A, C, W and Y, except for under clonal outbreaks, no vaccine was available against serogroup B. Recently, a four component vaccine, Bexsero(®), designed to prevent infection caused by this serogroup, has been approved in Europe and other Countries for use in individuals from two months of age and older. The active components of this vaccine are three recombinant proteins identified by reverse vaccinology combined with detergent extracted outer membrane vesicles (DOMV) prepared from a New Zealand epidemic strain. Considering their intrinsic complexity, we performed additional characterization of DOMVs on top of the standard quality control testing carried out for batch release. We applied the Hi3 label-free LC-MS(E) methodology to qualitatively and quantitatively characterize the DOMV protein content. We first, successfully investigated the robustness and the accuracy of the methodology for the DOMV characterization and we then applied it to compare six DOMV production lots. Around 100 proteins were quantified from each preparation. When classified according to their predicted cellular localization, about 90% of the total protein amount belongs consistently to the outer membrane compartment. Using nonparametric hypothesis testing and complementary log-log linear regression, the quantifications of a subset of 21 proteins common to all lots and including approximately 90% (85-92%) of the total protein amount quantified in any DOMV lot were found consistent across lots. The relevance of these results is two-fold, showing that the Hi3 quantification methodology is robust for a broad range of proteins and indicating that the manufacturing process currently used for the production of the Bexsero(®) DOMV components is highly reproducible and consistent.
doi_str_mv 10.1016/j.vaccine.2014.01.011
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1500691629</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1500691629</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-c3a0128b67943aad8889e9ce4abae296f1b3bb9fb3bf1569231ff56c183d3de93</originalsourceid><addsrcrecordid>eNo1kNtKAzEURYMgtlY_QcljfZgxJ5lJJ49a6gUqIl5ehyRzgilzqZOZ0v6UH-GXOcUKh71fFpvFIeQCWAwM5PUq3mhrfY0xZ5DEDIaDIzKGbCYinkI2IqchrBhjqQB1QkY8SSRPmBiTj5de15133urONzU1O7qcR0-v08UVbRxt-g5bWmFlWl0j3WDwtkS6bpsOfR32SPeJ9Ba3Advm55seRM7IsdNlwPNDT8j73eJt_hAtn-8f5zfLaA1cdpEVmgHPjJypRGhdZFmmUFlMtNHIlXRghDHKDekglYoLcC6VFjJRiAKVmJDp3-5g9NVj6PLKB4tlOdg2fcghZUwqkHyPXh7Q3lRY5OvWV7rd5f-_EL_mXmGn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1500691629</pqid></control><display><type>article</type><title>Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tani, Chiara ; Stella, Maria ; Donnarumma, Danilo ; Biagini, Massimiliano ; Parente, Pierino ; Vadi, Alessandro ; Magagnoli, Claudia ; Costantino, Paolo ; Rigat, Fabio ; Norais, Nathalie</creator><creatorcontrib>Tani, Chiara ; Stella, Maria ; Donnarumma, Danilo ; Biagini, Massimiliano ; Parente, Pierino ; Vadi, Alessandro ; Magagnoli, Claudia ; Costantino, Paolo ; Rigat, Fabio ; Norais, Nathalie</creatorcontrib><description>Meningococcal disease is a major cause of morbidity and mortality worldwide. Its epidemiology is currently dominated by five capsular serogroups (A, B, C, W, and Y). While effective vaccines already exist for serogroups A, C, W and Y, except for under clonal outbreaks, no vaccine was available against serogroup B. Recently, a four component vaccine, Bexsero(®), designed to prevent infection caused by this serogroup, has been approved in Europe and other Countries for use in individuals from two months of age and older. The active components of this vaccine are three recombinant proteins identified by reverse vaccinology combined with detergent extracted outer membrane vesicles (DOMV) prepared from a New Zealand epidemic strain. Considering their intrinsic complexity, we performed additional characterization of DOMVs on top of the standard quality control testing carried out for batch release. We applied the Hi3 label-free LC-MS(E) methodology to qualitatively and quantitatively characterize the DOMV protein content. We first, successfully investigated the robustness and the accuracy of the methodology for the DOMV characterization and we then applied it to compare six DOMV production lots. Around 100 proteins were quantified from each preparation. When classified according to their predicted cellular localization, about 90% of the total protein amount belongs consistently to the outer membrane compartment. Using nonparametric hypothesis testing and complementary log-log linear regression, the quantifications of a subset of 21 proteins common to all lots and including approximately 90% (85-92%) of the total protein amount quantified in any DOMV lot were found consistent across lots. The relevance of these results is two-fold, showing that the Hi3 quantification methodology is robust for a broad range of proteins and indicating that the manufacturing process currently used for the production of the Bexsero(®) DOMV components is highly reproducible and consistent.</description><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2014.01.011</identifier><identifier>PMID: 24462403</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Bacterial Outer Membrane Proteins - analysis ; Chromatography, Liquid ; Electrophoresis, Polyacrylamide Gel ; Mass Spectrometry ; Meningococcal Vaccines - analysis ; Quality Control</subject><ispartof>Vaccine, 2014-03, Vol.32 (11), p.1273-1279</ispartof><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24462403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tani, Chiara</creatorcontrib><creatorcontrib>Stella, Maria</creatorcontrib><creatorcontrib>Donnarumma, Danilo</creatorcontrib><creatorcontrib>Biagini, Massimiliano</creatorcontrib><creatorcontrib>Parente, Pierino</creatorcontrib><creatorcontrib>Vadi, Alessandro</creatorcontrib><creatorcontrib>Magagnoli, Claudia</creatorcontrib><creatorcontrib>Costantino, Paolo</creatorcontrib><creatorcontrib>Rigat, Fabio</creatorcontrib><creatorcontrib>Norais, Nathalie</creatorcontrib><title>Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Meningococcal disease is a major cause of morbidity and mortality worldwide. Its epidemiology is currently dominated by five capsular serogroups (A, B, C, W, and Y). While effective vaccines already exist for serogroups A, C, W and Y, except for under clonal outbreaks, no vaccine was available against serogroup B. Recently, a four component vaccine, Bexsero(®), designed to prevent infection caused by this serogroup, has been approved in Europe and other Countries for use in individuals from two months of age and older. The active components of this vaccine are three recombinant proteins identified by reverse vaccinology combined with detergent extracted outer membrane vesicles (DOMV) prepared from a New Zealand epidemic strain. Considering their intrinsic complexity, we performed additional characterization of DOMVs on top of the standard quality control testing carried out for batch release. We applied the Hi3 label-free LC-MS(E) methodology to qualitatively and quantitatively characterize the DOMV protein content. We first, successfully investigated the robustness and the accuracy of the methodology for the DOMV characterization and we then applied it to compare six DOMV production lots. Around 100 proteins were quantified from each preparation. When classified according to their predicted cellular localization, about 90% of the total protein amount belongs consistently to the outer membrane compartment. Using nonparametric hypothesis testing and complementary log-log linear regression, the quantifications of a subset of 21 proteins common to all lots and including approximately 90% (85-92%) of the total protein amount quantified in any DOMV lot were found consistent across lots. The relevance of these results is two-fold, showing that the Hi3 quantification methodology is robust for a broad range of proteins and indicating that the manufacturing process currently used for the production of the Bexsero(®) DOMV components is highly reproducible and consistent.</description><subject>Bacterial Outer Membrane Proteins - analysis</subject><subject>Chromatography, Liquid</subject><subject>Electrophoresis, Polyacrylamide Gel</subject><subject>Mass Spectrometry</subject><subject>Meningococcal Vaccines - analysis</subject><subject>Quality Control</subject><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kNtKAzEURYMgtlY_QcljfZgxJ5lJJ49a6gUqIl5ehyRzgilzqZOZ0v6UH-GXOcUKh71fFpvFIeQCWAwM5PUq3mhrfY0xZ5DEDIaDIzKGbCYinkI2IqchrBhjqQB1QkY8SSRPmBiTj5de15133urONzU1O7qcR0-v08UVbRxt-g5bWmFlWl0j3WDwtkS6bpsOfR32SPeJ9Ba3Advm55seRM7IsdNlwPNDT8j73eJt_hAtn-8f5zfLaA1cdpEVmgHPjJypRGhdZFmmUFlMtNHIlXRghDHKDekglYoLcC6VFjJRiAKVmJDp3-5g9NVj6PLKB4tlOdg2fcghZUwqkHyPXh7Q3lRY5OvWV7rd5f-_EL_mXmGn</recordid><startdate>20140305</startdate><enddate>20140305</enddate><creator>Tani, Chiara</creator><creator>Stella, Maria</creator><creator>Donnarumma, Danilo</creator><creator>Biagini, Massimiliano</creator><creator>Parente, Pierino</creator><creator>Vadi, Alessandro</creator><creator>Magagnoli, Claudia</creator><creator>Costantino, Paolo</creator><creator>Rigat, Fabio</creator><creator>Norais, Nathalie</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140305</creationdate><title>Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine</title><author>Tani, Chiara ; Stella, Maria ; Donnarumma, Danilo ; Biagini, Massimiliano ; Parente, Pierino ; Vadi, Alessandro ; Magagnoli, Claudia ; Costantino, Paolo ; Rigat, Fabio ; Norais, Nathalie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-c3a0128b67943aad8889e9ce4abae296f1b3bb9fb3bf1569231ff56c183d3de93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Bacterial Outer Membrane Proteins - analysis</topic><topic>Chromatography, Liquid</topic><topic>Electrophoresis, Polyacrylamide Gel</topic><topic>Mass Spectrometry</topic><topic>Meningococcal Vaccines - analysis</topic><topic>Quality Control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tani, Chiara</creatorcontrib><creatorcontrib>Stella, Maria</creatorcontrib><creatorcontrib>Donnarumma, Danilo</creatorcontrib><creatorcontrib>Biagini, Massimiliano</creatorcontrib><creatorcontrib>Parente, Pierino</creatorcontrib><creatorcontrib>Vadi, Alessandro</creatorcontrib><creatorcontrib>Magagnoli, Claudia</creatorcontrib><creatorcontrib>Costantino, Paolo</creatorcontrib><creatorcontrib>Rigat, Fabio</creatorcontrib><creatorcontrib>Norais, Nathalie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tani, Chiara</au><au>Stella, Maria</au><au>Donnarumma, Danilo</au><au>Biagini, Massimiliano</au><au>Parente, Pierino</au><au>Vadi, Alessandro</au><au>Magagnoli, Claudia</au><au>Costantino, Paolo</au><au>Rigat, Fabio</au><au>Norais, Nathalie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2014-03-05</date><risdate>2014</risdate><volume>32</volume><issue>11</issue><spage>1273</spage><epage>1279</epage><pages>1273-1279</pages><eissn>1873-2518</eissn><abstract>Meningococcal disease is a major cause of morbidity and mortality worldwide. Its epidemiology is currently dominated by five capsular serogroups (A, B, C, W, and Y). While effective vaccines already exist for serogroups A, C, W and Y, except for under clonal outbreaks, no vaccine was available against serogroup B. Recently, a four component vaccine, Bexsero(®), designed to prevent infection caused by this serogroup, has been approved in Europe and other Countries for use in individuals from two months of age and older. The active components of this vaccine are three recombinant proteins identified by reverse vaccinology combined with detergent extracted outer membrane vesicles (DOMV) prepared from a New Zealand epidemic strain. Considering their intrinsic complexity, we performed additional characterization of DOMVs on top of the standard quality control testing carried out for batch release. We applied the Hi3 label-free LC-MS(E) methodology to qualitatively and quantitatively characterize the DOMV protein content. We first, successfully investigated the robustness and the accuracy of the methodology for the DOMV characterization and we then applied it to compare six DOMV production lots. Around 100 proteins were quantified from each preparation. When classified according to their predicted cellular localization, about 90% of the total protein amount belongs consistently to the outer membrane compartment. Using nonparametric hypothesis testing and complementary log-log linear regression, the quantifications of a subset of 21 proteins common to all lots and including approximately 90% (85-92%) of the total protein amount quantified in any DOMV lot were found consistent across lots. The relevance of these results is two-fold, showing that the Hi3 quantification methodology is robust for a broad range of proteins and indicating that the manufacturing process currently used for the production of the Bexsero(®) DOMV components is highly reproducible and consistent.</abstract><cop>Netherlands</cop><pmid>24462403</pmid><doi>10.1016/j.vaccine.2014.01.011</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1873-2518
ispartof Vaccine, 2014-03, Vol.32 (11), p.1273-1279
issn 1873-2518
language eng
recordid cdi_proquest_miscellaneous_1500691629
source MEDLINE; Elsevier ScienceDirect Journals
subjects Bacterial Outer Membrane Proteins - analysis
Chromatography, Liquid
Electrophoresis, Polyacrylamide Gel
Mass Spectrometry
Meningococcal Vaccines - analysis
Quality Control
title Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T16%3A59%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quantification%20by%20LC-MS(E)%20of%20outer%20membrane%20vesicle%20proteins%20of%20the%20Bexsero%C2%AE%20vaccine&rft.jtitle=Vaccine&rft.au=Tani,%20Chiara&rft.date=2014-03-05&rft.volume=32&rft.issue=11&rft.spage=1273&rft.epage=1279&rft.pages=1273-1279&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2014.01.011&rft_dat=%3Cproquest_pubme%3E1500691629%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1500691629&rft_id=info:pmid/24462403&rfr_iscdi=true